Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated by Analysts at TD Cowen

Research analysts at TD Cowen initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating on the stock.

Other equities research analysts have also issued reports about the stock. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. BMO Capital Markets upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Jefferies Financial Group raised their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price for the company. Finally, Guggenheim increased their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Trading Down 1.6 %

Shares of CNTA stock opened at $16.74 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The company has a market cap of $2.21 billion, a PE ratio of -10.94 and a beta of 1.53. The stock’s fifty day moving average price is $16.90 and its two-hundred day moving average price is $14.24.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the completion of the sale, the insider now owns 183,266 shares of the company’s stock, valued at approximately $2,818,631.08. This represents a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 2,592 shares of the business’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44. Following the completion of the transaction, the chief executive officer now owns 630,661 shares in the company, valued at $9,661,726.52. This trade represents a 0.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 368,023 shares of company stock valued at $6,335,574. 11.59% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC boosted its position in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP grew its stake in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP bought a new stake in Centessa Pharmaceuticals in the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC bought a new stake in Centessa Pharmaceuticals in the second quarter worth approximately $99,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.